Stark Neurosciences Research Institute 5-year Report : simplebooklet.com

3 Letter from the Executive Director .................................4Institute Growth .................................................5Committees, Memberships and Employee Recruitment ....................6Pilot Programs and Space ..............................................7TREAT-AD news release ................................................8MODEL-AD news release...............................................10Education Programs.............................................12MedNeuro Program ...................................................13Undergrad Research and Summer Symposium...........................14Impactful Seminars .............................................15Research Interest Groups ........................................16Addiction, Advanced Imaging, Neurodegenerative Disorders...............17Neurodevelopment, Ocular Neurobiology, Pain ...........................18Psychiatric Disorders, Spinal Cord and Brain Injury, Stem Cell .............19Core Facilities ..................................................20Behavioral Phenotyping Core ..........................................21Biomarker, Electrophysiology, Flow Cytometry .......................... 22In vivo Imaging, Microscopy, Neurochemistry ........................... 23DEI Eorts .....................................................23Giving Information ..............................................25Donor Stories ..................................................26Fellow and her donor form deep friendship ............................. 26Room for Innovation ................................................. 28In Memorium ...................................................30TABLE OF CONTENTSFive-Year Report Stark Neurosciences Research Institute

Page 3

4 Colleagues,I’ve been privileged to lead Stark Neurosciences Research Institute (SNRI) since I joined Indiana University School of Medicine in 2016. It’s humbling to lead a team of talented researchers, postdocs, students and sta who embody excellence in supporting the advancement of neuroscience research at the medical school.We’ve experienced tremendous growth over the past several years. Our National Institutes of Health (NIH) grant funding increased by 53%—from $49.6 million in 2018 to $75 million in 2022. The research programs created through these federal funding dollars encompass multiple areas of neuroscience, from addiction and pain to stem cell and advanced imaging. Our top ve NIH-funded research programs focus on investigating Alzheimer’s disease and related dementias, which aligns with our neurodegenerative disorders research interest group— the largest group of investigators at the institute.In addition to our robust funding, we’ve added nearly 40 faculty investigators since 2018, bringing us to more than 100 primary and aliate members. Our members have faculty appointments in departments across the university, which includes IU School of Medicine campuses in Indianapolis, Muncie and Terre Haute as well as IU-Indianapolis and IU-Bloomington. The creation of nine research interest groups and multiple service core facilties has allowed researchers to collaborate on groundbreaking studies and discoveries like never before. Our expertise includes addiction, advanced imaging, neurodegenerative disorders, neurodevelopment, ocular neurobiology, pain, psychiatric disorders, spinal cord and brain injury, and stem cell research.Our mission to develop collaborative neuroscience research is also evident in our educational programming. The Medical Neuroscience Graduate Program (MedNeuro) is a highly competitive graduate program for trainees pursuing a PhD or MD/PhD. Under the leadership of internationally-recognized neuroscientists, close to 40 students each academic year study molecular mechanisms, cells, systems, behavior, translational neuroscience and diseases of the nervous system. Many MedNeuro graduates have gone on to work as postdoctoral researchers at prominent universities. The MedNeuro program was awarded an NIH T32 training grant supporting four predoctoral trainees and four postdoctoral trainees, giving our learners even more opportunities to advance in their careers. Each year, our trainees present their studies at the Stark Summer Science Symposium, a two-day meeting focused on neuroscience research.Not only do we have accomplished researchers, trainees and sta, but we’re also a team that cares. In 2020, we created a Diversity, Equity, Inclusion and Wellness (DEIW) Committee to enhance the understanding of DEIW issues and to encourage participation in trainings and professional activities that promote cultural competencies with people from diverse backgrounds. Of note, the group created the Women in Neuroscience (WiN) Committee that has instilled a mentoring program, networking events and career development awards. We’ve also focused on diversifying speakers for our weekly seminar series, gathering experts from dierent research backgrounds, ethnicities and universities. Our goal is to make Stark Neurosciences Research Institute a safe space for teaching, learning and investigating.Sincerely,Bruce Lamb, PhDIU Distinguished ProfessorExecutive Director, Stark Neurosciences Research InstituteRoberts Family Professor of Alzheimer’s Disease ResearchCo-Director, Neuroscience InstituteLETTER FROM THE EXECUTIVE DIRECTORMISSION STATEMENTOur mission is to bring together the scientic community in a dynamic, collaborative organization that advances discovery of neuroscience-related disease mechanisms and therapeutic strategies, as well as disseminates and applies this knowledge to prevent, treat and cure disease.Five-Year Report Stark Neurosciences Research Institute

Page 4

Page 5

6INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research InstituteCommittees and MembershipSNRI restructured its membership in the summer of 2020. Full-time faculty members from IU or those from another institution actively being recruited to the university can apply for membership. The investigators must conduct and actively publish neuroscience-related research to be considered for primary membership. Other faculty on the clinical track without conducting neuroscience research, neuroscience faculty from other universities, or emeritus and retired faculty from IU can apply for aliate membership. Primary and aliate members have access to core facilities and research interest groups, and primary members can apply for SNRI leadership positions, serve on committees, and are eligible to mentor Medical Neuroscience Graduate Program students. SNRI leadership also restructured and added new committees to accommodate the growth of new investigators, cores, and employees. The institute created a seminar committee, space and construction impact committee, cores committee, communications committee, and a diversity, equity, inclusion, and wellness (DEIW) committee. The DEIW committee has subcommittees to coordinate and develop more initiatives for the institute. Employee Expansion and Investigator RecruitmentOver the past several years, SNRI has recruited nearly 40 faculty from outside the university and across IU and IU School of Medicine campuses. Their additions have led to new research interest groups, such as ocular neurobiology, neurodevelopment, stem cell and advanced imaging. Many researchers have opened laboratories in the Neurosciences Research Building (NB) and the Biotechnology and Research Training Center (BRTC) and continuously collaborate across multiple disciplines in the institute. In addition to investigator recruitment, the SNRI administration created several new positions and hired individuals to support the institute in various ways, including event planning, research core management, communications, IT support, administration and nance and education program coordination. The SNRI operations team also created additional positions to manage the growth of laboratory space in the NB and the BRTC.

Page 6

7 INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research InstitutePilot ProgramsSNRI created two pilot programs in 2021 supporting Alzheimer’s disease research and neuroimaging research at IU School of Medicine. Pre-Clinical Neuroimaging Research Pilot Grant This program facilitates the generation of new knowledge in the neurosciences through the development of funded research programs and provides seed-support up to $10,000 for innovative, high-risk animal imaging projects using the Bruker BioSpec 9.4T PET-MRI scanner in the Indiana Institute for Biomedical Imaging Sciences In Vivo Imaging Core. The pilot grant is funded by the Roberts Neuroscience Imaging Research Fund. Alzheimer’s Disease Pre-Clinical Translational Science Grant This program enhances the approach to the selection and evaluation of drug discovery targets for Alzheimer’s disease and provides research support up to $50,000 for innovative work that is in scope and aligned with the research activities of the IU School of Medicine-Purdue TREAT-AD Center. The pilot grant is funded by the Roberts Alzheimer’s Disease Drug Discovery Fund. SpaceResearch space utilization and optimization/maximization has been a top priority for SNRI since opening its Neurosciences Research Building (NB) in 2014. In conjunction with the IU School of Medicine Dean’s Oce of Space Planning and Utilization, SNRI leadership have repurposed and reimagined space as the institute has grown and recruited world-class scientic investigators and clinicians; 32 investigators operate their laboratories in the NB. The 138,000-square-foot research building adjoins the IU Health Neuroscience Center in downtown Indianapolis, resulting in a more than 400,000-square-foot center with a modern, expertly designed space for collaboration, innovation and education among physicians and researchers. Additionally, ve SNRI investigators have lab space in the Biotechnology and Research Training Center (BRTC), located a mile west of the NB. Since 2018, the SNRI Operations Team has repurposed nearly 8,000 square feet of wet lab and lab support space on four oors of the ve-oor NB for 15 investigator-led labs and core services. Following SNRI’s expansion to the BRTC in summer 2020, more than 4,500 square feet of wet lab space was repurposed for four investigators as well as for core services. SNRI will grow into the 11-story medical education and research building IU School of Medicine is constructing directly south of the NB. Dave and Susan Roberts, who have already invested more than $10 million toward neuroscience research, have made a commitment to outt a suite of neurodegenerative disorders research labs in the new building, which is slated to open in late 2024. The labs will focus on Alzheimer’s disease and related dementias, but researchers there will also seek answers for Parkinson’s and Huntington’s diseases and ALS. The gift is expected to support lab space for 42 researchers, faculty and lab support spaces, precision tools for research and specialty areas such as brain and tissue banks.

Page 7

8INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research InstituteIU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery centerIndiana University School of Medicine has been awarded a grant expected to total $36 million over ve years from the National Institutes of Health to launch a drug discovery center to accelerate the development of promising treatments for Alzheimer’s disease. The center is a strategic partnership with the Purdue Institute for Drug Discovery. It is one of only two such multi-institution teams in the nation selected as part of a new federal program intended to “improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline,” according to the National Institute on Aging, which is part of the NIH and is funding the program. “There is much work to be done to solve the mysteries of Alzheimer’s and improve the lives of individuals and families aected by this insidious and devastating disease,” IU President Michael A. McRobbie said. “To this end, Indiana University is deeply committed to expediting the development of innovative medications and treatments for Alzheimer’s disease—building upon the leading role our School of Medicine has played in discovering ways of predicting onset of the disease, presenting new therapeutic targets and developing research tools used by scientists around the world. “We are extremely grateful to the National Institutes of Health for this extraordinary grant that will further IU’s robust eorts to advance the scientic research needed to fulll our vision of slowing—and ultimately defeating—a disease that has resisted eective treatment for far too long.” The IU-led center, called Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD), will initially focus on proteins, or targets, related to the brain’s immune system that may contribute to Alzheimer’s disease. They will be culled from an extensive list of potential targets nominated by researchers at elite medical institutions across the nation as part of the NIA-led Accelerating Medicines Partnership on Alzheimer’s Disease. October 2019

Page 8

9 INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research InstituteThere is a growing body of evidence that certain genes associated with the immune system may be linked to Alzheimer’s disease, opening a new avenue for research and drug discovery. This focus on the immune system is consistent with IU’s Precision Health Grand Challenge initiative. The establishment of the NIA-funded drug discovery centers comes at a time when many pharmaceutical companies are scaling back eorts in the area or refocusing their strategies following setbacks of expensive, late-stage drug trials. The goal is to develop high-quality research tools and new technologies needed to broaden the number of targets being investigated, and for universities to conduct the earliest stages of drug discovery, eliminating some of the risk for pharmaceutical companies, biotech rms and other investors. “The challenges of nding eective medicines for Alzheimer’s disease are numerous and complex,” said Alan Palkowitz, a senior research professor at IU School of Medicine who will lead the center. “It is going to require a very strong ecosystem that is enriched with scientic diversity and new collaborative models. The emergence of centers like this, which can not only perform cutting-edge science but also inform the community with results, are going to be important partners with all groups who are committed to creating breakthrough therapies.” Palkowitz was recruited to IU School of Medicine through the IU Precision Health Initiative in late 2018 after 28 years at Eli Lilly and Co., where he most recently served as vice president of discovery chemistry research. The center’s co-principal investigator is Bruce Lamb, executive director of the Stark Neurosciences Research Institute, Roberts Family Professor of Alzheimer’s Disease Research and director of the NIA-funded IU/Jackson Laboratory Alzheimer’s Disease Precision Models Center at IU School of Medicine. Alzheimer’s disease is the most common cause of dementia in the aging population, aecting an estimated 5.5 million Americans, about 110,000 of whom live in Indiana. The national number is projected to rise as high as 14 million by 2050. There are currently no treatments to prevent or slow progression of the disease. Notably, all data, methods and tools generated by the NIA-funded centers will rapidly be made available to researchers from academia, nonprot research organizations, biotech and the pharmaceutical industry for use in drug discovery and basic biology research. “We are honored to be selected to provide national leadership as the NIH moves more aggressively into funding new translational infrastructure programs for Alzheimer’s disease and to expand the pipeline of promising drug candidates,” said Dr. Jay L. Hess, dean of IU School of Medicine and IU’s executive vice president for university clinical aairs. “This center complements and builds on our extensive expertise in Alzheimer’s disease research and is a critical piece of the puzzle needed “Indiana University is deeply committed to expediting the development of innovative medications and treatments for Alzheimer’s disease”

Page 9

10 IU School of Medicine Alzheimer’s study awarded nearly $50 million by NIH to continue groundbreaking researchThe second largest federally funded research program at Indiana University School of Medicine will receive $48.8 million over the next ve years, fueling the work of researchers as they seek to discover treatments for Alzheimer’s disease. The National Institute on Aging (NIA), the largest branch for Alzheimer’s disease research within the National Institutes of Health (NIH), has renewed Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) for a second ve-year cycle, worth about $9.8 million a year through at least 2026. In 2016, the NIA established MODEL-AD—a consortium of experts at IU School of Medicine, Jackson Laboratory, the University of Pittsburgh School of Medicine and Sage Bionetworks— to generate and validate new animal models of late-onset Alzheimer’s disease as well as perform rigorous preclinical testing of potential therapeutics. The NIA awarded the program $25 million for its rst ve years and extended the grant into a sixth year in 2021 for $5 million. “Over the past several years, the Alzheimer’s disease research portfolio at IU School of Medicine has greatly expanded in scope, from understanding the basic disease mechanisms to moving novel therapeutics into patients and everything in between, said Bruce Lamb, PhD, executive director of Stark Neurosciences Research Institute. “MODEL-AD is a critical piece of that puzzle as we continue to develop the next generation of animal models.” Close to 55 million people worldwide—including more than 6 million in the United States—are estimated to have Alzheimer’s disease or related dementias, according to the World Health Organization. In the U.S., that’s expected to rise to about 13 million people by 2050. INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research InstituteSeptember 2022

Page 10

11 INSTITUTE GROWTHFive-Year Report Stark Neurosciences Research Institute“MODEL-AD arose out of the Precision Health Initiative and is an example of what strong leadership and a sustained focus on a prioritized area can achieve,” said Jay L. Hess, MD, PhD, MHSA, executive vice president for university clinical aairs and dean of IU School of Medicine. “We set out to be a national resource in the battle against Alzheimer’s disease and under Dr. Lamb’s leadership we are delivering on that vision.” MODEL-AD consists of multiple cores across the four institutions. The Bioinformatics and Data Management Core (BDMC) is led by Gregory Carter, PhD at the Jackson Laboratory in Bar Harbor, Maine; the Preclinical Testing Core (PTC) is directed by Paul Territo, PhD at IU School of Medicine and Stacey Rizzo, PhD at the University of Pittsburgh School of Medicine; and the Disease Modeling Project (DMP) is directed by Gareth Howell, PhD and Michael Sasner, PhD at the Jackson Laboratory and Lamb and Adrian Oblak, PhD at IU School of Medicine. All animal models, protocols and validation data studied by MODEL-AD are shared online to the greater research community through the AD Knowledge Portal, run by Sage Bionetworks. “The renewal of the MODEL-AD grant allows us to continue building robust research infrastructure to advance our understanding of Alzheimer’s disease and evaluate potential novel therapeutics as a resource for the greater research community,” said Rizzo. “The renewal will allow us to build on our progress of generating and characterizing new animal models to study late-onset Alzheimer’s disease and enable the acceleration of clinical trials by improving the translational potential of promising investigational compounds.” “We are excited to enhance and expand our eorts using the latest molecular discoveries, computational strategies, and emerging technologies to transform preclinical studies of Alzheimer’s disease,” said Carter. “By combining the resources of The Jackson Laboratory with our partner institutions, we are eager to continue making foundational contributions to the NIA’s Translational Initiatives to nd treatments for this yet-uncurable disease.” For the past three years, MODEL-AD has been among the top ve NIH-funded research studies at IU School of Medicine; four of those programs were for Alzheimer’s disease research, in alignment with the school’s top priorities. MODEL-AD is now the second largest funded grant at the school. “IU School of Medicine is a national leader in Alzheimer’s disease research. MODEL-AD has already led important strides in our understanding of Alzheimer’s disease, and we are delighted to receive this substantial NIH grant that will allow us to continue our work to support Alzheimer’s disease research and the development of new therapies for this devastating disorder,” said Tatiana Foroud, PhD, executive associate dean for research aairs. “For the past three years,MODEL-AD has been among thetop ve NIH-funded research studies at IU School of Medicine”

Page 11

Page 12

13 EDUCATION PROGRAMSFive-Year Report Stark Neurosciences Research InstituteMedical Neuroscience Graduate ProgramThe Medical Neuroscience Graduate Program (MedNeuro) is an interdisciplinary program housed at SNRI and is the largest graduate program at IU School of Medicine. The graduate student candidate pool comprises students enrolled through IU School of Medicine’s Indiana Biomedical Gateway (IBMG) and Medical Scientist Training (MSTP) programs with highly diverse academic backgrounds. Faculty who are eligible to mentor and teach MedNeuro students have primary academic appointments in their departments and are also primary members of SNRI.Approximately 50% of all MedNeuro graduate students are working on projects on Alzhiemer’s disease or related dementias; others are working on topics including addiction, neurodevelopment, advanced imaging, ocular neurobiology, neuropsychiatric disorders, pain, sensory systems, spinal cord and brain injury and stem cell research.The MedNeuro education team has led extensive eorts over the past ve years to overhaul the MedNeuro program for graduate and medical students, creating a highly competitive and respected program of study that sets students up for success in neuroscience and related careers. The core curriculum encompasses multiple levels of study, including molecular mechanisms, cells, systems, behavior, translational neuroscience and diseases of the nervous system.The MedNeuro graduate program, from 2018 to 2022, had more than 40 graduate students enrolled each academic year. Collectively, MedNeuro graduate students have contributed to more than 400 studies published as articles or abstracts, with trainees appearing as the rst author of approximately 40% of the studies. MedNeuro trainees have an average number of 3.9 publications, and many appear in top-tier journals. In 2020, the MedNeuro program was awarded an NIH T32 training grant (1T32AG071444-01: Training Grant on Alzheimer’s Disease and ADRD at Indiana University) supporting four predoctoral trainees and four postdoctoral trainees and also enlisting 25 faculty focused on data science, non-invasive imaging, the development and study of animal models, genomics, epidemiology, drug development and discovery and clinical studies and trials.“I knew I wanted to do neurodegeneration research, and when I began interviewing, I found that Stark was highly collaborative and had a really strong focus on neurodegeneration”- Sam Colin, Graduate Student“[I have learned] not what to think, but how to think... you have a front-row seat to observe how to solve problems nobody knows the answer to, design experiments that move the eld forward, and do good science.”-David Haggerty, Graduate Sturent

Page 13

14EDUCATION PROGRAMSFive-Year Report Stark Neurosciences Research InstitutePostdoctoral TrainingPostdoctoral researchers at SNRI train with faculty investigators across IU School of Medicine departments focusing on neuroscience, which include Neurology, Neurological Surgery, Psychiatry, Ophthalmology, Otolaryngology, Medical and Molecular Genetics, Anatomy, Cell Biology and Physiology, Microbiology and Immunology, Pathology and Laboratory Medicine, Radiology and Imaging Services and Pharmacology and Toxicology. Faculty investigators throughout IU School of Medicine conduct a broad range of translational, clinical and basic research, and postdoctoral appointees and fellows benet from this robust research environment. This training and working environment enables postdoctoral researchers to hone their research knowledge and skills for career advancement.Summer Undergraduate Research Program The SNRI education program has developed a competitive, intensive, paid eight-week Summer Undergraduate Research Program open to students enrolled in undergraduate programs across the US with an interest in pursuing a career in neuroscience research. Participants receive a competative stipend and housing. The program provides a strong foundation for students to develop research skills and is designed to prepare students for graduate school. Undergraduate students have the opportunity to work with mentors in addiction, neurodegenerative disorders, neurodevelopment, advanced imaging, ocular neurobiology, neuropsychiatric disorder, pain, sensory systems, spinal cord/brain injury and stem cell research. The education team recruits students at events throughout the country, attracting more than 300 applicants per year. Stark Summer Science SymposiumThe Stark Summer Science Symposium was initiated in 2019 and has since become an annual event—even during the COVID-19 pandemic in 2020 when the symposium was successfully held virtually—enabling trainees to connect and share their research. The symposium provides a platform for predoctoral and postdoctoral trainees to share their research, exchange ideas and network with one another.Predoctoral and postdoctoral trainees share their research in a series of talks and poster sessions representing all of the major research focus areas of SNRI. Awards are presented for the best posters and oral presentations.

Page 14

15 Jose Moron Concepcion, PhD“Opioid-induced plasticity and the intersection with pain” May 2019 Jose Moron Concepcion is an expert in pain and addiction research at Washington University School of Medicine in St. Louis. He is the Henry E. Mallinckrodt Professor of Anesthesiology and is the director of research in the Department of Anesthesiology. He spoke about neurocircuits and synaptic plasticity underlying pain’s eects on cognition. This work is very important for understanding the impact of the opioid epidemic on people. Tasneem Sharma, PhD“Eye on the Future: Therapeutic Potential and Preclinical Applications” Feb. 2021Tasneem Sharma, a newly recruited SNRI member and assistant professor in the Department of Ophthalmology at IU School of Medicine, researches the retinal neuronal cell death that is characteristic of glaucoma, a major case of vision loss. Her expertise in induced pluripotent stem cell-based retinal ganglion cell research adds to a growing focus on this area at SNRI. Additionally, she has developed technology to culture human eyes under conditions of dierential pressure, as seen in glaucoma, and is exploring innovative neuroprotective approaches in this model. D. James Surmeier, PhD“Calcium, Bioenergetics and Parkinson’s Disease” Oct. 2019D. James Surmeier is chair of neuroscience at Northwestern University and is a very prestigious speaker. He is one of the leaders in the eld of basal ganglia research. He described his cutting-edge work on mechanisms of dopamine cell death in Parkinson’s disease. He discussed a novel concept of energy balance of dopamine neurons being a critical component of the neurons’ longevity. Hugo Tejeda, PhD“Opiod control of prefrontal cortical emotional and information processing” Nov. 2021Hugo Tejeda is a Stadtman Investigator at the National Institutes of Health. His role at the NIH is a prestigious position for a junior faculty member. He spoke about neurocircuits of addiction. Students and postdoctoral researchers at SNRI reported that he was one of the best speakers and learned so much from him. Tejeda was able to converse with trainees in their native Spanish language. IMPACTFUL SPEAKERSSEMINARSFive-Year Report Stark Neurosciences Research Institute

Page 15

Page 16

17 AddictionSNRI faculty in the Addiction Research Interest Group have a wide range of research programs focused on the cellular, molecular and behavioral correlates of addiction to alcohol, cannabis, methamphetamine, nicotine, opiates and food. Investigators are interested in the mechanisms and consequences of alcoholism, drug addiction and obesity. The National Institute on Alcohol Abuse and Alcoholism-funded Indiana Alcohol Research Center, which supports thematic research in the genetic determinants of alcoholism, comprises SNRI investigators and collaborators from the Addictions Neuroscience Graduate Program oered through the IUPUI School of Science. SNRI addiction-related research areas include but are not limited to behavioral pharmacology, electrophysiology, microdialysis, genetics, novel human interventions, alcohol administration paradigms (both preclinical and human) and human behavioral and neuroimaging studies.Advanced Imaging Investigators in the Advanced Imaging (in vivo) Research Interest Group at SNRI are involved with the Advanced Imaging Research Program (AIRP) in the Indiana Institute of Biomedical Imaging Sciences (IIBIS) and the Center for Neuroimaging (CfN), which support a wide array of cutting-edge neuroimaging research at IU School of Medicine. With state-of-the-art preclinical and clinical magnetic resonance imaging and positron emission tomography scanners, faculty develop innovative methods and technologies to expand and optimize the information we can extract from the brain and explore novel ways of processing and analyzing complex datasets. There is a strong focus on integrative approaches that bring together forward-thinking ways of conceptualizing how dierent types of advanced imaging data relate to each other and untangling the intersection of brain imaging information, neuropsychological variables and genetic and peripheral biomarkers. The power of these technologies is then applied to various neurological and psychiatric disorders, including normative aging and neurodegenerative disorders (with a focus on Alzheimer’s disease), alcohol and substance use disorders, traumatic brain injury and adolescent and adult neuropsychiatric disorders.Neurodegenerative DisordersIU School of Medicine is home to robust, productive and renowned research centers, laboratories, and programs that collaborate to advance research on Alzheimer’s disease and other dementias. The neurobiology and molecular genetics of neurodegenerative disorders are signicant research focus areas of SNRI and IU School of Medicine. SNRI neurodegenerative disorders researchers predominantly investigate Alzheimer’s disease. Researchers in the Neurodegenerative Disorders Research Interest Group are exploring the causes of Alzheimer’s disease and related dementias, searching for new methods to detect the disease early and discovering the latest advances to slow and prevent the disease—no matter how long it takes. Neuroscience experts collaborate on basic and translational science programs within the research institute through multiple nationally funded studies, centers and consortia throughout the school of medicine.Five-Year Report Stark Neurosciences Research Institute

Page 17

18 NeurodevelopmentThe Neurodevelopment Research Interest Group at SNRI focuses on both preclinical and clinical research. The clinical aspect is focused on understanding how dierences in the structure and function of the developing brain aect cognition, behavior and psychosocial outcomes. Related work includes structural and functional MRI studies of cognitive functioning (e.g., language, memory and executive functioning) and neuroimaging that correlates in healthy adolescent and pediatric neuropsychiatric populations, including children with temporal lobe-onset seizures, those who have experienced mild traumatic brain injury, concussion or cancer treatment and those with disruptive behavioral disorders or who are at risk for developing substance abuse disorders. The preclinical basic science developmental neurobiology research program at IU School of Medicine covers a broad range of topics. Researchers are interested in the molecular mechanisms guiding cell fate specication (dierentiation), survival and apoptosis, axon guidance and synaptogenesis. Pluripotent stem cells are utilized to produce sensory neurons, inner ear hair cells and retinal ganglion cells to identify epigenetic programs of neural dierentiation. Ultimately, these developmental pathways are triggered upon exposure to addictive drugs and neurodegenerative conditions, leading to synapse and circuit remodeling. Ocular NeurobiologyThe Ocular Neurobiology Research Interest Group at SNRI is a growing group of investigators studying the most visible part of the nervous system—the eye. Many faculty in the research interest group are aliated with the Eugene and Marilyn Glick Eye Institute and the Department of Ophthalmology at IU School of Medicine. Research areas of interest include understanding degenerative diseases of the retina, such as glaucoma, diabetic retinopathy, inherited retinal degenerations and age-related macular degeneration, plus the basic mechanisms of photoreceptor function and the manifestations of other neurological disorders within the visual system. Faculty use numerous techniques, including human and animal in vivo imaging, disease modeling with induced pluripotent stem cells, small molecule screening and therapeutic discovery and advanced microscopy. PainThe SNRI Pain Research Interest Group includes investigators studying a broad range of topics using multiple pain models. Areas of interest include electrophysiology, immunohistochemistry, tract-tracing studies, opto- and chemo-genetics, calcium imaging and behavioral studies. Within this group, researchers work with several diverse causes of pain, including inammation, surgery, chemotherapy and neuropathic pain. Often, these studies intersect with spinal cord injury and traumatic brain injury models. Five-Year Report Stark Neurosciences Research Institute

Page 18

19 Psychiatric DisordersInvestigators in the Psychiatric Disorders Research Interest Group at SNRI explore the neurophysiological basis of psychiatric disorders. These research areas were the original focus of the IU School of Medicine Medical Neuroscience Graduate Program, and that tradition continues. Areas of interest include animal models and human studies of anxiety, depression, bipolar disorder, schizophrenia, conduct disorder and autism. The laboratories involved represent a wide range of disciplines, including behavioral pharmacology, genetics, human behavior, neuroimaging, anxiety, depression, autism, opto-and chemo-genetics, electrophysiology and neuroimmunology animal modeling.Spinal Cord and Brain InjuryThe Spinal Cord and Brain Injury Research Interest Group at SNRI, also called the Indiana Spinal Cord and Brain Injury Research Group (ISCBIRG), comprises a critical mass of key principal investigators studying the molecular mechanisms underlying spinal cord injury and traumatic brain injury. They are developing novel repair strategies to promote neural reorganization and functional recovery in experimental models of these injuries. The long-term goal of these studies is to translate promising treatments from animal models to humans. Additionally, several faculty conduct behavioral, pharmacological, and neuroimaging research in human pediatric, adolescent and adult traumatic brain injury. Stem CellSeveral research teams throughout SNRI focus on using stem cells to better understand human nervous system development. Researchers use stem cells as a tool to elucidate mechanisms underlying neurodegenerative disorders or to replace cells that are lost in disease states. Researchers range from established investigators with strong backgrounds in stem cell research to those who include stem cell research as part of a broader research program. Collectively, researchers within the research institute work collaboratively on many basic and translational studies utilizing stem cells as part of many studies funded federally by the National Institutes of Health and the Department of Defense or by private foundations. Five-Year Report Stark Neurosciences Research Institute

Page 19

20CORE FACILITIESFive-Year Report Stark Neurosciences Research InstituteBehavioral Phenotyping CoreLeadership: Kathryn D. Fischer, PhD Year Established: 2018 The Behavioral Phenotyping Core (BPC) is a state-of-the art facility where investigators can study the behavior of animal models. Housed on the fourth and fth oors of the Neurosciences Research Building, the core, available to all IU School of Medicine investigators and external users, oers more than 1,300 square feet of dedicated testing space. The core has a diverse array of equipment to assess general health, sensory, motor, aective and cognitive function of rats and mice following genetic, environmental or pharmacological manipulations. The BPC oers the following services: in-vivo physiology and behavioral assessments in rodents, graduate student and post-doctoral training in the behavioral sciences, and PI consultations for publication and grant support. BPC users represent PIs, postdocs and students representing eight dierent departments and centers as well as contracted work for three local biotech companies. Since 2018, the BPC has written more than 55 letters of support for National Institutes of Health and Department of Defense grants, training fellowships and intramural applications, representing 12 departments within IU School of Medicine and IUPUI. Additionally, they have written support letters for ve external universities and biotech companies. In October 2021, the BPC was awarded a grant funded by Elevate Ventures to investigate the therapeutic potential of Scioto’s proprietary activated bacterial therapeutic (ABT) compound in a mouse model of autism spectrum disorder. The BPC has also conducted preclinical studies sponsored by Karuna Therapeutics to investigate the activity of the muscarinic agonist Xanomeline in rodent models of psychosis, both alone and as an adjunctive treatment with clinically used antipsychotic medications. This work is in support of their investigative Phase III clinical compound KarXT. CORE FACILITIES

Page 20

21 CORE FACILITIESFive-Year Report Stark Neurosciences Research InstituteBiomarker CoreLeadership: Je Dage, PhD Year Established: 2021 The SNRI Biomarker Core provides biomarker services to investigators within SNRI, IU School of Medicine and external users. Available equipment includes nCounter MAX system, GeoMx DSP system, Meso QuickPlex SQ120, Ella and Simoa HD-X. Multiplexing of targets in tissues or on a slide, investigators can detect changes in their samples and target specic pathways of interest in disease. The Biomarker Core also oers services to design and validate custom kits for customers. Investigators will be charged for core employee time, as well as the cost of kits and materials. Since launching in July 2021, the core has written ve letters of support and been involved in three grant submissions. Electrophysiology CoreLeadership: Brady Atwood, PhD Year Established: 2019 The Electrophysiology Core provides brain slice recordings for SNRI members, IU School of Medicine investigators and external users. Services include synaptic plasticity, basal neurotransmission, cellular excitability/membrane properties, optogenetics, chemogenetics (DREADDs), pharmacological responses, ion channel function and electrophysiological assessments of animal models. The Electrophysiology Core has contributed to high-impact publications in Science Advances, Molecular Degeneration and Nature Neuroscience. The core has also helped obtain two large National Institutes of Health grants for SNRI investigators. Flow Cytometry CoreYear Established: 2018 The Flow Cytometry Core in Stark Neurosciences Research Institute at IU School of Medicine oers state-of-the-art ow cytometry analysis and cell sorting for SNRI investigators. Several thousand cells can be analyzed and processed using the equipment in a minute. The core oers BD LSRFortessa X-20 Cell Analyzer and Sony Biotechnology MA900 Multi-Application Cell Sorter for use. Since the core was created in 2018, 11 faculty laboratories—atotal of 21 users— have beneted from its services. The Flow Cytometry Core has helped multiple high-impact publications, National Institute of Health grants and several postdoctoral fellowships.

Page 21

22CORE FACILITIESFive-Year Report Stark Neurosciences Research InstituteIn-Vivo Imaging Core Leadership: Yu-Chien Wu, MD, PhD Year Established: 2019 The Roberts Translational Imaging Facility is a joint venture between SNRI and the Indiana Institute for Biomedical Imaging Sciences. It was established in 2019 to oer a variety of preclinical imaging services for Clinical and Translational Sciences Institute investigators across campuses. Anchored by the state-of-the-art Bruker BioSpec 9.4T PET-MRI scanner, the MRI and PET technologies oer neuroimaging, cardiovascular imaging, musculoskeletal imaging, vasculature imaging, abdominal imaging and whole-body imaging with a variety of tracers including tau, amyloid, dopamine, synaptic density, FDG and FET for small animals using MRI and PET technologies. Microscopy CoreYear Established: 2018 The Microscopy Core in SNRI provides high-tech microscopy equipment for institute members. The core oers access to the Nikon A1R Confocal Microscope and an analysis station. Since opening in 2018, the core has helped over 50 users and 17 labs across the institute. Research conducted in the Microscopy Core has directly impacted nearly a dozen investigator publications in peer-reviewed journals and multiple National Institutes of Health grants and fellowship awards for postdoctoral researchers. Neurochemistry CoreLeadership: Eric Engleman, PhD Year Established: 2021 The Neurochemistry Core at SNRI completes services from design to sample collection in the interstitial space of the CNS or subcutaneous space. The core can perform conventional or quantitative microdialysis to examine acute drug eects or assess neuroadaptive eects after long-term treatment or aging, respectively. The core is also set up to measure amino acids, monoamines, and some drugs and metabolites. The Neurochemistry Core was integral to Eric Engleman receiving funding of the Roberts Alzheimer’s Disease Translational Science Grant. Currently, the core is working with the Purdue Proteomics Core to develop a method to conduct proteomics proling of microdialysis samples.

Page 22

23 DEIW INITIATIVESFive-Year Report Stark Neurosciences Research InstituteDIVERSITY, EQUITY, INCLUSION AND WELLNESS COMMITTEESNRI created a Diversity, Equity, Inclusion, and Wellness (DEIW) Committee in 2020. The committee’s goals are to enhance the leadership’s understanding of DEIW issues and encourage the community to participate in trainings and professional activities that would enhance their cultural competencies and experiences with people from diverse backgrounds.When the DEIW Committee launched, they immediately started organizing virtual seminars with experts to address inclusivity in the workplace, including sessions on creating workplace culture, conict management, ombuds oce resources, unconscious bias and cultural humility. SNRI leadership and the IU School of Medicine Honor Code highlight the importance of faculty commitment to diversity and inclusion, and annual diversity training is required for faculty who teach in the Medical Neuroscience Graduate Program at SNRI.The DEIW Committee comprises four subcommittees focusing on specic needs: inclusion and awareness, professional development, wellness and women in neuroscience. Over the past few years, the committee has greatly impacted the SNRI Black in Neuro, AISES SNRI sponsors Black in Neuro, a registered 501(c)(3) organization that aims to diversify the neurosciences by building a community that celebrates and empowers Black scholars and professionals in neuroscience-related elds. The organization hosts Black in Neuro Week each year, a virtual event that oers free educational content and networking opportunities for the Black in Neuro community and allies. SNRI also sponsors the American Indian Science and Engineering Society (AISES) National Conference each year, the premier event for Indigenous STEM professionals and students, attracting over 2,500 members and attendees from the US and Canada.Women in Neuroscience The SNRI Women in Neuroscience (WiN) subcommittee is a women-oriented group that includes, but is not restricted to, female scientists and trainees pursuing a career in neuroscience research. They foster relationships and gather ideas leading to members’ professional enrichment and career development while recognizing the many obstacles faced. The committee has hosted networking events, created a mentoring program and sponsored a funding award. The SNRI Women in Neurosciences Research and Career Development Award funds two specialized research projects or career development activities twice per year for women at the postdoctoral, graduate or undergraduate level conducting research in an SNRI lab.

Page 23

24DEIW INITIATIVESFive-Year Report Stark Neurosciences Research InstituteProfessional Development Opportunities The Professional Development Subcommittee established a grant crafting workshop to assist researchers with training and mentorship plans, grant writing timeline planning, and grant reviewer comment responses. This professional development series has provided support to all, with an emphasis on supporting underrepresented minorities in the science community. The subcommittee also developed diversity scholarships for IU undergraduates and hosted a book club with selections from diverse authors. Wellness Events The Wellness Subcommittee sponsors and organizes events and activities to promote physical and mental wellness development while providing a comfortable and safe environment. The committee hosted activities for Mental Health Day, cookie decorating contests, a walking club, stairs challenge, monthly tness events and an event at Cirque Indy. They also shared healthy recipes and workouts in the SNRI newsletter and opened a wellness room in the building.

Page 24

25 GIVING INFORMATIONFive-Year Report Stark Neurosciences Research InstituteDONATE TO SNRISNRI is at the forefront of advancing neuroscience research and investigating groundbreaking therapeutic strategies for disorders of the nervous system. The research institute was founded to enable rigorous investigations of normal and abnormal functions in the central nervous system using the most advanced technologies and to apply the resulting discoveries to treat devastating neurological disorders. The concept—to provide a venue where scientists and clinicians from dierent disciplines would collaborate to advance understanding of the nervous system—is central to the institute.The institute—a staple of IU School of Medicine and Indianapolis for nearly two decades—has experienced tremendous growth over the past several years. From 2018–2022, SNRI investigators were awarded more than 130 new grants from the National Institutes of Health (NIH), resulting in $344 million of total funding. Of the $214.8 million in NIH funding IU School of Medicine received in 2022, a third of that—$75 million—came from SNRI investigators.The largest grants awarded to investigate Alzheimer’s disease include the following:• $56 million for Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)• $48.8 million for Indiana University/Jackson Laboratory Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD)• $36 million for IU School of Medicine-Purdue Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD)• $28.9 million for National Centralized Repository for Alzheimer’s Disease and Related Dementias• $15 million for the Indiana Alzheimer’s Disease Research CenterSNRI investigators are also training the next generation of neuroscientists—and the future is bright at IU School of Medicine. More than 75 faculty members teach graduate students in the Medical Neuroscience Graduate Program. Each student in the program has a mentor they work with in a laboratory and an advisory committee to assist in creating a personalized curriculum that supports their planned thesis work. Postdoctoral researchers also work alongside faculty to conduct bench work in specialized neuroscience-related elds.Are you interested in giving to SNRI? In addition to the institute’s main fund, each research interest group at SNRI has its own research and education fund through IU School of Medicine Gift Development that supports this vital work.For more information on giving, please contact Andrea Spahn-McGraw with IU School of Medicine Gift Development: anspahn@iu.edu or 317-278-2124

Page 25

26 “Very quickly it evolved into a real friendship of mutual respect, and we enjoyed talking, sharing and laughing.” Shortly into the pandemic, Hande Karahan, PhD, and Nancy Carpenter, the donor of a fellowship that supported Karahan’s research a year prior, decided to reconnect. They could only meet outside, several feet apart, and spent their time together on long walks, hiking in local parks and visiting horses. Those walks and talks in nature have since led to a strong friendship, a connection both say has changed their lives for the better. In January 2020, Karahan, the recipient of the 2019 Sarah Roush Memorial Fellowship in Alzheimer’s Disease Research, presented her project to Nancy and James Carpenter, Tom and Dianne Trauring and several Indiana University School of Medicine Alzheimer’s researchers. The fellowship, established by the Indiana Alzheimer’s Disease Research Center, is funded through a generous donation from the Carpenters and a matching contribution from Stark Neurosciences Research Institute. Nancy Carpenter and Dianne Trauring are the daughters of Sarah Roush, who died of Alzheimer’s disease in 2010. Carpenter said she was impressed with how Karahan presented the science behind her Alzheimer’s disease research to a lay audience, and she enjoyed Karahan’s “sweet demeanor and smile.” “I kind of thought originally that I would reach out to her in case she needed a ‘mom type person’ being so far away from Turkey and her mom,” Carpenter said. “Very quickly it evolved into a real friendship of mutual respect, and we enjoyed talking, sharing and laughing.” Karahan, assistant research professor of medical and molecular genetics, is Turkish, and she moved to the United States in 2017 as a postdoctoral researcher at the Mayo Clinic, working for the laboratory of Jungsu Kim, PhD. Kim, the P. Michael Conneally Professor of Medical and Molecular Genetics, moved his laboratory to IU School of Medicine in 2018. Typically, when donors make contributions to research, Kim said, the transaction is mostly nancial. Being the Sarah Roush Fellow signicantly helped Karahan nancially and scientically, she said, but the major gain from the fellowship was her friendship with Carpenter. DONOR STORIES:FELLOW AND HER DONOR FORM DEEP FRIENDSHIPFive-Year Report Stark Neurosciences Research InstituteMarch 2022

Page 26

27 “This was a human connection; it wasn’t just nancial support,” Karahan said. “Nancy and Jim have become my family here in the United States.” Kim said that while the pandemic has been dicult for most, it’s especially hard for foreign-born postdoctoral researchers living thousands of miles away from family. “I’m so grateful they’ve provided Hande with emotional support,” Kim said. “I think that’s the most important type of support she could’ve received from a donor.” Karahan and Carpenter both have shared interests in horses and nature. When Karahan lived in Turkey, she would ride horses, and that hobby was reinvigorated. The Carpenters own horses, which Karahan and Carpenter would visit. Karahan also signed up for horseback riding lessons. “I enjoyed watching her progress from the sidelines, taking photos and cheering her on,” Carpenter said. “I knew it would be meaningful for her to have photos to send to her family.” They’ve also spent time hiking in parks and learning from each other’s cultures. Karahan has made Carpenter Turkish food and taught her how to make Turkish coee, while Carpenter taught Karahan how to make maple syrup. They try and meet up multiple times a month and often visit Newelds. As their friendship has grown over time, the roots are grounded in Alzheimer’s disease research. Carpenter’s mother, Sarah Roush, started showing signs of the neurodegenerative disease at the age of 70. The disease also took hold of her grandmother decades earlier. “My mom would be so honored, and she would have loved Hande so much,” Carpenter said. Close to 55 million people worldwide—including more than 6 million in the U.S.—are estimated to have Alzheimer’s disease or related dementias, according to the World Health Organization. In the U.S., that’s expected to rise to about 13 million people by 2050. Karahan’s research that was supported by the fellowship investigated the function of a gene associated with Alzheimer’s disease in the brain’s immune cells. Karahan published her study in a high-impact paper and received three separate grants supporting her research from the National Institute on Aging, the National Institutes of Health (NIH) branch for Alzheimer’s research, resulting in $7.8 million over the next ve years. When Karahan heard her paper was accepted, she rst called her parents and then Carpenter. “None of us could imagine that this project would lead to that strong of a relationship,” Karahan said. “Their fellowship led to really big grants and will denitely aect the future of our projects and our lab; but also personally, it changed my life, too.” Karahan said Carpenter has been a calming presence to her when she’s been stressed about her research or about the pandemic, providing Karahan with wisdom and encouragement. “If I have a small part in helping her attain her goals, I feel very happy and gratied by that,” Carpenter said. “She’s a special person and has been a gift to my life.” DONOR STORIES:FELLOW AND HER DONOR FORM DEEP FRIENDSHIP““My mom would be so honored, and she would have loved Hande so much,” Carpenter said. Five-Year Report Stark Neurosciences Research Institute

Page 27

28 DONOR STORIES:ROOM FOR INNOVATIONFive-Year Report Stark Neurosciences Research InstituteBy Bobby KingDirector of Development and Alumni Communications, Oce of Gift DevelopmentDave and Susan Roberts know what it’s like to watch people they love slip into the shadows of memory loss. For Dave, it was his dad. For Susan, her mother. And they’ve heard the stories of others who’ve shared the same pain. “Everybody we know has a relative or a friend’s relative that has dealt with it,” said Susan, an Indiana University graduate. “Sometimes it’s a ve-or-10-year process. It’s just miserable for the person and their whole family.” So, when they began to think about research areas where they could direct their charitable giving, Dave and Susan came to a swift conclusion. “We looked at how much money was dedicated to other diseases, and we felt that not enough was going to Alzheimer’s research,” Dave said. “We were looking for a research organization that was looking for the cause—and for a cure. We also wanted a place that could help patients with the daily destruction of a meaningful life from dementia symptoms—and the emotionally frustrating and nancial devastation their families endure.” They found it in IU School of Medicine. And, since 2017, Dave, a retired manufacturing executive and auto enthusiast, and Susan, his wife of 50 years, have invested more than $10 million in neuroscience research. Now, the Indiana couple has made a new commitment to outt a suite of neurodegenerative disease research labs in the School of Medicine’s new medical education and research building, which is due to open in late 2024. The labs will focus on Alzheimer’s disease and related dementias, but researchers there will also seek answers for Parkinson’s and Huntington’s diseases, and ALS, also known as Lou Gehrig’s disease. Part of the purpose of the new building is to provide much-needed research space for the School of Medicine, which has seen its National Institutes of Health research November 2022

Page 28

29 Five-Year Report Stark Neurosciences Research InstituteThe Roberts gift is expected to support equipping lab space for 42 researchers, faculty and lab support spaces, precision tools for research, and specialty areas such as brain and tissue banks. “We are so grateful for this generous gift from Dave and Susan,” said IU School of Medicine Dean Jay L. Hess, MD, PHD, MHSA. “Their support of our neuroscience research has been nothing short of extraordinary. This gift comes at a crucial time, giving us room to expand our work, attract new talent, and make important discoveries.” The Roberts have previously supported brain imaging research and drug discovery projects, fellowships for young researchers, and a powerful PET-MRI scanner that’s one of a few of its kind in the world. They also funded the creation of a new faculty chair used to recruit Bruce Lamb, PhD, from the Cleveland Clinic. Lamb—the Roberts Family Professor of Alzheimer’s Disease Research—is an internationally-recognized expert in Alzheimer’s disease research and executive director of Stark Neurosciences Research Institute at IU. Since his arrival in 2015, Lamb has come to know Dave and Susan well. He’s discussed with them where Alzheimer’s research is headed and has been impressed not only by their generosity but also their grasp of what he and others are trying to do. “Dave and Susan have not only been tremendous partners in our work, but they’re also just good people,” Lamb said. “They ask great questions and they have a heartfelt interest in sparing future generations from the devastating eects of neurodegenerative disease. There is no question that their ongoing support has helped speed our eorts. We’re so thankful for their support.” Dave had a lengthy career in business. And he’s sponsored, collected and driven race cars—so he appreciates the importance of going fast. But he also understands the years of work that go into building a strong business or a fast car. He says, when it comes to neurodegenerative diseases, he knows the returns on his investments could take years or even decades. “Would we like to see something immediately? Of course. But we recognize that research is going to take a long time,” Dave said. “So, we recognize it is a long-term ght to get there, but we’re OK with that.” DONOR STORIES:ROOM FOR INNOVATION

Page 29

30IN MEMORIAMFive-Year Report Stark Neurosciences Research InstituteXiao-Ming Xu, PhD January 11, 1952–December 2, 2022SNRI remembers the life of Xiao-Ming Xu, PhD, the Mari Hulman George Professor of Neuroscience Research, who passed away Dec. 2, 2022, at the age of 70 after a courageous battle with cancer.Xu joined the research faculty in the Department of Neurological Surgery at IU School of Medicine in 2007. He received continuous support for his research for over 20 years from the National Institutes of Health, Department of Defense, and the Department of Veteran Aairs. His work concentrated on neuroprotection, axonal regeneration, and recovery from traumatic spinal cord and brain injuries. Xu led the Indiana Spinal Cord and Brain Injury Research Group (ISCBIRG) at SNRI, where he was a primary member.Xu published over 200 research papers, and in 2020, he was listed among the top 2 percent of scientists worldwide. During his legacy at IU, Xu served as a valuable mentor to undergraduate students, residents and postdoctoral candidates in pursuit of neurosurgery careers.The Department of Neurological Surgery and SNRI held the Xiao-Ming Xu Memorial Symposium on March 13, 2023, to honor his accomplishments in the eld. Over a dozen neuroscience investigators spoke about Xu’s impact on spinal cord and brain injury research and shared about their own research during the four-hour symposium.Peter Roach, PhDJune 8, 1948–March 11, 2022SNRI remembers the life of Peter Roach, PhD, professor of biochemistry and molecular biology and an IU Distinguished Professor, who passed away March 11, 2022.Roach joined IU School of Medicine in 1979. During his career, he received many accolades, both as a faculty member and as a mentor, including being named Chancellor’s Professor of IUPUI in 2000 and IU Distinguished Professor in 2008. A strong believer in the value of basic research as applied to disease, Roach, a primary member of SNRI, published more than 200 peer-reviewed papers and for 41 years held the longest-funded National Institutes of Health grant at IU. Roach earned international recognition for his studies on glycogen metabolism and its regulation. In the last 15 years, his glycogen expertise led him to studies of Lafora Disease where he made outstanding contributions to the pathogenesis of this deadly childhood disorder.Roach was the founding principal investigator and director of a T32 training grant in diabetes and obesity. His approach to student training is a model for faculty members not only at IU, but throughout the world. Under his mentorship, 18 students earned PhD or master’s degrees and 20 postdoctoral fellows studied under his direction.

Stark Neurosciences Research Institute 5-year Report

Page 1

Page 2